ReviewJournal of osteoporosis2015
Type 1 diabetes and osteoporosis: from molecular pathways to bone phenotype.
Review in Journal of osteoporosis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Fracture risk in young and middle-aged adults with type 1 diabetes mellitus: A systematic review and meta-analysis.Clinical endocrinology · 2018Pooled it
- Increased risk of vertebral fracture in patients with diabetes: a meta-analysis of cohort studies.International orthopaedics · 2016Pooled it
- Integrative gene target mapping, RNA sequencing, in silico molecular docking, ADMET profiling and molecular dynamics simulation study of marine derived molecules for type 1 diabetes mellitus.Molecular diversity · 2026Article
- Bone Benefits After Simultaneous Pancreas-kidney Transplantation Compared With the Pretransplant Period.Transplantation · 2026Article
- Insulin Deficiency Exacerbates Muscle Atrophy and Osteopenia inInternational journal of molecular sciences · 2025Article
- Effect of Chrysin, a Flavonoid Present in Food, on the Skeletal System in Rats with Experimental Type 1 Diabetes.Nutrients · 2025Article
- Bone Loss in Diabetes Mellitus: Diaporosis.International journal of molecular sciences · 2024Review
- Osteocalcin, miR-143, and miR-145 Expression in Long-Standing Type 1 Diabetes Mellitus and Their Correlation with HbA1c.Indian journal of clinical biochemistry : IJCB · 2024Article
- FNDC5/irisin ameliorates bone loss of type 1 diabetes by suppressing endoplasmic reticulum stress‑mediated ferroptosis.Journal of orthopaedic surgery and research · 2024Article
- Bone Metabolism Parameters in Azerbaijani Pre and Postmenopausal Women with Diabetes.Iranian journal of public health · 2023Article
- Article
- Diabetic Bone Disease and Diabetic Myopathy: Manifestations of the Impaired Muscle-Bone Unit in Type 1 Diabetes.Journal of diabetes research · 2022Review
- Article
- Lower bone mineral density and higher bone resorption marker levels in premenopausal women with type 1 diabetes in Japan.Journal of diabetes investigation · 2021Article
- Critical review of bone health, fracture risk and management of bone fragility in diabetes mellitus.World journal of diabetes · 2021Review
- Article
- Proteomic study of in vitro osteogenic differentiation of mesenchymal stem cells in high glucose condition.Molecular biology reports · 2020Article
- Lower estimated bone strength and impaired bone microarchitecture in children with type 1 diabetes.BMJ open diabetes research & care · 2020Article
- In vivo Labeling of Bone Microdamage in an Animal Model of Type 1 Diabetes Mellitus.Scientific reports · 2019Article
- Insulin Receptor deletion in S100a4-lineage cells accelerates age-related bone loss.Bone reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The link between type 1 diabetes mellitus (DM1) and osteoporosis, identified decades ago, has gained attention in recent years. While a number of cellular mechanisms have been postulated to mediate this association, it is now established that defects in osteoblast differentiation and activity are the main culprits underlying bone fragility in DM1. Other contributing factors include an accumulation of advanced glycation end products (AGEs) and the development of diabetes complications (such as neuropathy and hypoglycemia), which cause further decline in bone mineral density (BMD), worsening geometric properties within bone, and increased fall risk. As a result, patients with DM1 have a 6.9-fold increased incidence of hip fracture compared to controls. Despite this increased fracture risk, bone fragility remains an underappreciated complication of DM1 and is not addressed in most diabetes guidelines. There is also a lack of data regarding the efficacy of therapeutic strategies to treat osteoporosis in this patient population. Together, our current understanding of bone fragility in DM1 calls for an update of diabetes guidelines, better screening tools, and further research into the use of therapeutic strategies in this patient population.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.